Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OrthoPediatrics Corp. (NASDAQ: KIDS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. OrthoPediatrics is a Delaware-incorporated orthopedic medical device company focused on pediatric orthopedics, and its filings offer detailed information on its financial condition, operations, and governance.
Investors can review current reports on Form 8-K, where OrthoPediatrics reports material events such as quarterly earnings releases, preliminary unaudited revenue updates, revisions to financial guidance, and presentations to investors and analysts. The company also uses Form 8-K to disclose board changes, including director retirements and new appointments, and to furnish press releases related to business developments like OPSB expansion.
In addition to 8-Ks, OrthoPediatrics files periodic reports such as Form 10-Q and Form 10-K, which contain unaudited and audited financial statements, segment information, and risk factor discussions referenced in its news releases. These documents provide context on revenue by category (trauma and deformity, scoliosis, sports medicine/other procedures, and specialty bracing), operating expenses, restructuring charges, intangible asset impairments, and non-GAAP measures such as adjusted EBITDA.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, major cost items, and business drivers. Users can also track real-time updates as new filings are posted to EDGAR, including any future Forms 4 reporting insider transactions, proxy statements detailing director compensation, and other governance-related documents. This centralized view of KIDS filings allows investors, analysts, and researchers to examine OrthoPediatrics’ regulatory history, financial disclosures, and corporate actions in one place, supported by AI-generated explanations that clarify complex sections of the filings.
ORTHOPEDIATRICS CORP executive Joseph W. Hauser reported a stock grant and related tax sale. He acquired 65,700 shares of Common Stock on March 15, 2026 as a grant at $0.00 per share, increasing his direct holdings to 203,363 shares.
On March 16, 2026, 8,596 shares were sold at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares. After these transactions, he directly owned 194,767 shares of Common Stock, including restricted stock awards totaling 155,805 shares.
OrthoPediatrics Corp executive Fred Hite, the COO and CFO, reported both a stock grant and a related share sale. On March 15, 2026, he acquired 77,405 shares of Common Stock as a grant at $0.00 per share. On March 16, 2026, he sold 12,993 shares of Common Stock at $17.25 per share to satisfy tax withholding obligations upon vesting of restricted shares.
After these transactions, Hite directly owned 277,477 shares of OrthoPediatrics Common Stock, which the disclosure states includes restricted stock awards totaling 197,765 shares.
OrthoPediatrics Corp President and CEO David R. Bailey reported an open-market sale of 19,535 shares of common stock at $17.25 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations triggered when restricted stock vested, rather than as a discretionary portfolio move.
After this transaction, Bailey directly holds 298,020 shares of OrthoPediatrics common stock, which includes 187,891 shares of restricted stock awards. The sale represents only a portion of his overall equity position in the company.
OrthoPediatrics Corp President of Scoliosis Gregory A. Odle reported a stock compensation event combined with a tax-related share sale. He received a grant of 47,380 shares of common stock as a restricted stock award. The next day, 8,433 shares were sold specifically to satisfy tax withholding obligations upon vesting of restricted shares, according to the footnote. After these transactions, he directly holds 187,735 shares of common stock, which the disclosure states includes restricted stock awards totaling 121,054 shares.
OrthoPediatrics Corp General Counsel Daniel J. Gerritzen reported compensation-related stock activity. On March 15, he acquired 47,380 shares of common stock as a grant or award at $0.00 per share. On March 16, he sold 8,614 shares at $17.25 per share.
According to a footnote, the shares sold on March 16 were used to satisfy tax-withholding obligations tied to the vesting of restricted shares, rather than a discretionary sale. After these transactions, he directly holds 149,533 shares of common stock, which includes restricted stock awards totaling 121,054 shares.